ReviewFrontiers in cell and developmental biology2021
Bacterial Translocation as Inflammatory Driver in Crohn's Disease.
Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- The Impact of Dietary Interventions on the Microbiota in Inflammatory Bowel Disease: A Systematic Review.Journal of Crohn's & colitis · 2024Pooled it
- A yeast-derived postbiotic fermentate rapidly modulates inflammatory cytokines and immune surveillance markers in healthy adults: a randomized double-blind placebo-controlled cross-over trial.Frontiers in nutrition · 2026Trial
- Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review).International journal of molecular medicine · 2026Review
- Diet, Ultra-Processed Foods, and Food Additives in Crohn's Disease: A Comprehensive Review.Nutrients · 2026Review
- Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan.Journal of gastroenterology · 2026Article
- In vitro modeling of inflammatory bowel diseases using a newly developed immunocompetent colon epithelial monolayer co-culture model.npj biomedical innovations · 2026Article
- Natural carrier-free self-assembled binary polyphenol nanoparticles remodel the gut microenvironment for inflammatory bowel disease prevention.Materials today. Bio · 2026Article
- TNFα signaling in radiation-induced chronic bowel dysfunction suggests therapeutic potential for IBD biologics.Molecular medicine (Cambridge, Mass.) · 2026Article
- Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions.Clinical and experimental medicine · 2026Review
- Retrospective analysis of intestinal flora alterations in adults with acute gastrointestinal injury.Frontiers in cellular and infection microbiology · 2026Article
- Microbial exopolysaccharides as bioactive modulators of intestinal health: a systematic review.Frontiers in nutrition · 2026Review
- Interpretable Artificial Neural Network Models for Predicting Anti-Adalimumab Immune Complex and Serum Drug Level in Crohn's Disease: A Proof-of-Concept Study.Pharmaceutics · 2025Article
- Porphyromonas gingivalis-induced glucose intolerance during periapical lesions requires its LPS throught a Th17 immune response.International journal of oral science · 2025Article
- The Potential Role of Microalgal Antioxidant Molecules on the Microbiota-Gut Axis in Inflammatory Bowel Diseases.Biomolecules · 2025Review
- Dietary Nitrogen and Its Role in the Gut Microbiome and Inflammatory Bowel Disease: A Narrative Review.Nutrients · 2025Review
- Working together: gut microbe-microbe interactions shape host inflammation.Infection and immunity · 2025Review
- Presence of viable gram-positive bacteria in blood of patients with inflammatory bowel disease is not affected by treatment.Scientific reports · 2025Article
- From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel Disease Management.Nutrients · 2025Review
- Common microbial signatures in blood and their amplification in clinical disorders.Gut microbes reports · 2025Review
- Navigating SARS-CoV-2-related immunopathology in Crohn's disease: from molecular mechanisms to therapeutic challenges.Virology journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract responsible for intestinal lesions. The multifactorial etiology attributed to CD includes a combination of environmental and host susceptibility factors, which result in an impaired host-microbe gut interaction. Bacterial overgrowth and dysbiosis, increased intestinal barrier permeability, and altered inflammatory responses in patients with CD have been described in the past. Those events explain the pathogenesis of luminal translocation of bacteria or its products into the blood, a frequent event in CD, which, in turn, favors a sustained inflammatory response in these patients. In this review, we navigate through the interaction between bacterial antigen translocation, permeability of the intestinal barrier, immunologic response of the host, and genetic predisposition as a combined effect on the inflammatory response observed in CD. Several lines of evidence support that translocation of bacterial products leads to uncontrolled inflammation in CD patients, and as a matter of fact, the presence of gut bacterial genomic fragments at a systemic level constitutes a marker for increased risk of relapse among CD patients. Also, the significant percentage of CD patients who lose response to biologic therapies may be influenced by the translocation of bacterial products, which are well-known drivers of proinflammatory cytokine production by host immune cells. Further mechanistic studies evaluating cellular and humoral immune responses, gut microbiota alterations, and genetic predisposition will help clinicians to better control and personalize the management of CD patients in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.